NCT02519322 - Neoadjuvant and Adjuvant Checkpoint Blockade | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 2, 2016

Primary Completion Date

January 26, 2023

Study Completion Date

January 26, 2023

Conditions

Cutaneous MelanomaMucosal MelanomaOcular MelanomaStage III Acral Lentiginous Melanoma AJCC v7Stage IIIB Cutaneous Melanoma AJCC v7Stage IIIB Uveal Melanoma AJCC v7Stage IIIC Cutaneous Melanoma AJCC v7Stage IIIC Uveal Melanoma AJCC v7Stage IV Acral Lentiginous Melanoma AJCC v6 and v7Stage IV Cutaneous Melanoma AJCC v6 and v7Stage IV Uveal Melanoma AJCC v7

Interventions

BIOLOGICAL

Ipilimumab

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

Nivolumab

Given IV

BIOLOGICAL

Relatlimab

Given IV

PROCEDURE

Therapeutic Conventional Surgery

Undergo surgery

Trial Locations (2)

10065

Memorial Sloan Kettering Cancer Center, New York

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER